Despite Hansoh Pharmaceutical's high P/E ratio, its minimal ...

Despite Hansoh Pharmaceutical's high P/E ratio, its minimal earnings growth and slower future growth vs. the market make its valuation questionable. Shareholders and investors may face disappointment as the high P/E isn't justified by the growth outlook.